"Keynote Lecture: New clues in AA pathophysiology"

ESH eLearning, Neal Young, 374848

Clinical and biological aspects of SAMD9 & SAMD9L syndromes

ESH eLearning, Marcin Wlodarski, 374846

New IBMFs

ESH eLearning, Thierry Leblanc, 374845

Disease progression and clinical outcomes in TBD

ESH eLearning, Sharon Savage, 374843

Telomeres biology in hematopoietic stem cell disorders

ESH eLearning, Tim Brümmendorf, 374842

Panel discussion

ESH eLearning, Faculty / Presenters, 374841

"Selected brief oral communication: Results of prospective hematologic surveillance with correlative single cell DNA sequencing in children with SAMD9/SAMD9L related bone marrow failure and Monosomy 7"

ESH eLearning, Nathan Gray, 374840

Management of Diamond-Blackfan anaemia (DBA)

ESH eLearning, Deena Iskander, 374839

Management of SDS

ESH eLearning, Akiko Shimamura, 374838

Ribosomes and hematopoiesis

ESH eLearning, Alan Warren, 374837

"Selected brief oral communication: Germline variants in MDM4 cause a disorder of p53 dysregulation and Insufficient Telomere Maintenance"

ESH eLearning, Robert Meyer, 374836

Gene therapy for Fanconi anaemia and other iBMF

ESH eLearning, Juan Bueren Roncero, 374835

Classical and new treatment of Fanconi anaemia

ESH eLearning, Carlo Dufour, 374834

Clonal tracking of hematopoietic stem cells

ESH eLearning, Peter Campbell, 374829

Clonal hematopoiesis in inherited BMFD

ESH eLearning, Coleman Lindsley, 374828

Inflamm-ageing of the hematopoietic system

ESH eLearning, Markus Manz, 374827

Welcome address

ESH eLearning, Faculty / Presenters, 374826

Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 374825

Panel Discussion

ESH eLearning, Faculty / Presenters, 374701

Interactive case: Gastric MALT lymphoma

ESH eLearning, Catherine Thieblemont, 374700

Case-based lecture: Waldenstrom Macroglobulinemia

ESH eLearning, Judith Trotman, 374699

Case-based lecture: Systemic marginal zone lymphoma

ESH eLearning, Stefano Luminari, 374698

Panel Discussion

ESH eLearning, Faculty / Presenters, 374695

Case-based lecture: What are the treatment options after CAR-T cells failure?

ESH eLearning, Roberta Di Blasi, 374694

Case-based lecture: AEs in CAR T and BITE therapy

ESH eLearning, Frederick Locke, 374692

Interactive case: Integrating bispecific antibodies into the treatment in large B-cell lymphoma

ESH eLearning, Martin Hutchings, 374691

Final vote

ESH eLearning, Faculty / Presenters, 374690

Con

ESH eLearning, Matthew Wilson, 374689

Pro

ESH eLearning, Christopher Fox, 374688

Introduction

ESH eLearning, Michael Crump, 374687

Discussion

ESH eLearning, Faculty / Presenters, 374686

CD19 CAR-T cell therapy for mantle cell lymphoma and follicular lymphoma

ESH eLearning, Pashna Munshi, 374685

CD19 CAR-T as second line therapy for diffuse large B-cell lymphoma

ESH eLearning, Frederick Locke, 374684

CD19 CAR-T mechanisms of action and resistance

ESH eLearning, Marco Ruella, 374683

Panel Discussion

ESH eLearning, Faculty / Presenters, 374682

Selected brief oral communication: Subcutaneous epcoritamab combined with R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma: phase 1/2 update

ESH eLearning, Michael Roost Clausen, 374681

Case-based lecture: Is auto-transplant over in diffuse large B-cell lymphoma?

ESH eLearning, Marek Trneny, 374680

Case-based lecture: Relapsed (not autologous stem cell transplant /CAR T eligible)

ESH eLearning, Armando Lopez-Guillermo, 374679

Case-based lecture: Front line therapy (focus on high risk)

ESH eLearning, Kim Linton, 374678

Case-based lecture: Consolidation radiation therapy in diffuse large B-cell lymphoma?

ESH eLearning, Viola Pöschel, 374677

Discussion

ESH eLearning, Faculty / Presenters, 374676

Autologous and allogeneic stem cell transplant for T-cell lymphoma

ESH eLearning, Silvia Montoto, 374674

Final vote

ESH eLearning, Faculty / Presenters, 374673

Con

ESH eLearning, Alison Moskowitz, 374672

Pro

ESH eLearning, Peter Borchmann, 374671

Introduction

ESH eLearning, Graham Collins, 374670

Panel Discussion

ESH eLearning, Faculty / Presenters, 374709

Selected brief oral communication: Subcutaneous epcoritamab combined with rituximab + lenalidomide for the treatment of patients with relapsed or refractory follicular lymphoma: phase 1/2 trial update

ESH eLearning, Lorenzo Falchi, 374669

Case-based lecture: Relapsed follicular lymphoma: which cellular therapy: Auto, Allo or CAR T, Bispecific

ESH eLearning, Caron Jacobson, 374668

Case-based lecture: Optimal front line approach for high-risk follicular lymphoma

ESH eLearning, Stefano Luminari, 374667

Case-based lecture: Understanding biology of high risk follicular lymphoma - EZH, a new target for follicular lymphoma?

ESH eLearning, Kai Hübel, 374666

Interactive case: Recognizing high risk

ESH eLearning, Jessica Okosun, 374665

Panel Discussion

ESH eLearning, Faculty / Presenters, 374664

Case-based lecture: Salvage therapy in peripheral T-cell lymphoma

ESH eLearning, Alison Moskowitz, 374663

Case-based lecture: Front-line 'personalized' therapy of common PTCL subtypes

ESH eLearning, Alison Moskowitz, 374662

Panel Discussion

ESH eLearning, Faculty / Presenters, 374660

Selected brief oral communication: Clinicopathological features and outcome of CD5 positive diffuse large B cell lymphoma and significance of CD5 expression strength: 10-year single center experience

ESH eLearning, Vojin Vukovic, 374659

Case-based lecture: Advanced - how to choose optimal therapy in the context of refining the risk assessment (TMT, Ctdna)

ESH eLearning, Anca Prica, 374657

Case-based lecture: Limited stage Hodgkin lymphoma

ESH eLearning, Marc Andre, 374656

Interactive case : Elderly patients with Hodgkin lymphoma: chemo or not chemo?

ESH eLearning, Graham Collins, 374655

Welcome address

ESH eLearning, Faculty / Presenters, 374654

Conference Book (PDF)

ESH eLearning, Faculty / Presenters, 374705

Selected abstract:Immunological response to sars-cov-2 after infection and/or vaccination among CML patients – a prospective study

ESH eLearning, Jorge Cortes, 374418

Selected abstract:Adverse impact of HMGCLL1 gene variant on treatment outcomes including response, failure and progression with imatinib can be abrogated by the use of 2nd generation tyrosine kinase inhibitor therapy in chronic myeloid leukemia

ESH eLearning, Dennis KIM, 374417

Selected abstract:Treatment and long-term follow-up of children with CML in chronic phase in the TKI Era: more than 2 decades of experience from the Tata Memorial Hospital paediatric CML cohort

ESH eLearning, Nirmalya ROY MOULIK, 374416

Patients perspective on cure in CML

ESH eLearning, Giora Sharf, 374415

20 years of evidence-based patient advocacy in CML: a story of close collaboration with researchers

ESH eLearning, Jan Geissler, 374414

Selected abstract: UK real world of experience of asciminib

ESH eLearning, Andrew Innes, 374410

Selected abstract:Clinical outcome of asciminib treatment in a real-world multi-resistant CML patient population

ESH eLearning, Camille C.B. Kockerols, 374409

Phase separation-based mechanisms underlying 3D chromatin structure reorganization and CML blast crisis

ESH eLearning, Greg Wang, 374401

Keynote Presentation:Clinical trials and the real world: how do they correlate

ESH eLearning, Dragana Milojkovic, 374408

Discussion

ESH eLearning, Faculty / Presenters, 374406

Asciminib

ESH eLearning, Delphine Rea, 374405

Next-generation cytogenomics in leukemia: opportunities for diagnosis and discovery

ESH eLearning, Steve Eacker, 374399

Ponatinib

ESH eLearning, Jorge Cortes, 374404

Introduction

ESH eLearning, Tim P. Hughes, 374403

Discussion

ESH eLearning, Faculty / Presenters, 374397

Intrinsic

ESH eLearning, Mirle Schemionek-Reinders, 374396

Extrinsic

ESH eLearning, Daniela Krause, 374395

Introduction

ESH eLearning, Ravi Bhatia, 374394

Selected abstract: Long-term treatment outcome and health-related qualityof life of patients with CML treated with TKIs: a single-center report

ESH eLearning, Hee Jeong Cho, 374393

Selected abstract:TFR after nilotinib or dasatinib 1st-line in chronic phase CML patients: characteristics and outcomes

ESH eLearning, Franck Nicolini, 374391

Selected abstract:Final result of TKI discontinuation trial with dasatinib for 2nd attempt of TFR after failing 1st attempt with imatinib: TFR accomplished by dasatinib (TRAD) trial

ESH eLearning, Dennis KIM, 374390

Keynote Presentation:TFR and Pro: Where do we stand? Where to go?

ESH eLearning, Susanne Saussele, 374389

Teamwork

ESH eLearning, Andreas Hochhaus, 374388

Selected abstract:Dose modification dynamics of ponatinib in patients with chronic-phase CML from the PACE and optic trials

ESH eLearning, Gianantonio Rosti, 374387

Selected abstract:Vodobatinib in chronic phase Ph+ CML - updated efficacy results

ESH eLearning, Jorge Cortes, 374386

Selected abstract: Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib vs bosutinib in patients with CML in chronic phase after ≥2 prior tyrosine kinase inhibitors: week 96 update

ESH eLearning, Andreas Hochhaus, 374384

Keynote Presentation:New drugs in CML: which, where and how

ESH eLearning, Valentin Garcia Gutiérrez, 374383

Cancer evolution ecosystems

ESH eLearning, Carlo Maley, 374382

Selected abstract: Deciphering the cooperative mechanism between asciminib and orthosteric inhibitors in stabilizing the inactive conformation of BCR-ABL1 compound mutants

ESH eLearning, Milad Rouhimoghadam, 374379

Selected abstract: Identification of key microRNAs as predictive biomarkers of nilotinib response in CML: a sub-analysis of the ENESTxtnd clinical trial

ESH eLearning, Andrew Wu, 374378

Selected abstract: Relationship between telomere length and clonal hematopoiesis of indeterminate potential in patients with CML at 1st diagnosis and during follow-up under TKI therapy

ESH eLearning, Anna D. Doleschall, 374377

Targeted protein degradation as a tool to probe non-kinase roles in CML

ESH eLearning, George Burslem, 374372

Validation of PROTACs as chemical tools and expanding the tool box of new E3 ligands

ESH eLearning, Stefan Knapp, 374371

General discussion

ESH eLearning, Faculty / Presenters, 374369

The LAST trial: the value of PRO after treatment discontinuation

ESH eLearning, Ehab Atallah, 374368

Lessons learnt from EURO-Ski: where now

ESH eLearning, Francois-Xavier Mahon, 374367

iCMLf Genomic Alliance – Goals and accomplishments through a global collaboration

ESH eLearning, Susan Branford, 374366

Current understanding mutation assessment and significance in CML

ESH eLearning, Simona SOVERINI, 374365